Literature DB >> 8720676

Indirect immunofluorescence study of the cornea and the conjunctiva in a xenogeneic system: analysis of humoral reactivity in patients with Wegener's granulomatosis.

U Przyklang1, B Nölle, E Reinhold-Keller, G Duncker.   

Abstract

BACKGROUND: Ocular involvement in patients with Wegener's granulomatosis (WG) can cause progressive loss of vision. The pathophysiological events leading to the WG-specific ocular inflammation are unknown.
METHODS: A method involving indirect immunofluorescence on bovine and porcine corneoconjunctival frozen sections was used to detect antibodies to corneal and conjunctival epithelium in serum samples from patients suffering from WG with ophthalmic involvement (orbital granuloma or ocular vasculitis, both active and inactive phase). Normal persons and WG patients without ophthalmic involvement served as control groups. Anti-human IgG, IgA and IgM were tested.
RESULTS: Five different immunofluorescence patterns could be distinguished in each species. There were differences in the reactivity with bovine and porcine tissue. Every pattern was caused mainly by human IgG. The antibodies were directed to the cell nuclei or to extranuclear structures. All patterns also occurred frequently in normal sera. No pattern was found that occurred specifically in the serum of patients with WG and ocular inflammation.
CONCLUSIONS: The results indicate that this immunofluorescence system does not detect a characteristic antibody profile that could be attributed to the serum of WG patients. Hence the approach lacks clinical usefulness as a diagnostic procedure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8720676     DOI: 10.1007/BF00695245

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  18 in total

1.  Ocular manifestations of Wegener's granulomatosis.

Authors:  B R STRAATSMA
Journal:  Am J Ophthalmol       Date:  1957-12       Impact factor: 5.258

2.  Ig-class specificity of ANCA.

Authors:  M R Daha; R J Falk
Journal:  Neth J Med       Date:  1990-04       Impact factor: 1.422

3.  [Wegener's granulomatosis: ocular manifestations, diagnosis and therapy].

Authors:  G Duncker; A Beigel; H Lehmann
Journal:  Klin Monbl Augenheilkd       Date:  1982-09       Impact factor: 0.700

4.  cANCA test and the detection of Wegener's disease in sclerokeratitis and uveitis.

Authors:  R J de Keizer; F J van der Woude
Journal:  Curr Eye Res       Date:  1990       Impact factor: 2.424

Review 5.  The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature.

Authors:  B F Haynes; M L Fishman; A S Fauci; S M Wolff
Journal:  Am J Med       Date:  1977-07       Impact factor: 4.965

6.  Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders.

Authors:  E Brouwer; J W Tervaert; G Horst; M G Huitema; M van der Giessen; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

Review 7.  'Classic' anti-neutrophil cytoplasmic autoantibodies (cANCA), 'Wegener's autoantigen' and their immunopathogenic role in Wegener's granulomatosis.

Authors:  W L Gross; E Csernok; B K Flesch
Journal:  J Autoimmun       Date:  1993-04       Impact factor: 7.094

8.  [A new seromarker: an aid in the differential diagnosis of unclear scleral processes].

Authors:  G Duncker; W L Gross
Journal:  Klin Monbl Augenheilkd       Date:  1987-03       Impact factor: 0.700

9.  Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils.

Authors:  R Goldschmeding; C E van der Schoot; D ten Bokkel Huinink; C E Hack; M E van den Ende; C G Kallenberg; A E von dem Borne
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

10.  Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme.

Authors:  J Lüdemann; B Utecht; W L Gross
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.